Last reviewed · How we verify

NCT05820139

Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery

Completed NA Last updated 29 April 2024
What this trial tests

NA trial testing Control Group in Voiding Dysfunction in 100 participants. Completed in 26 February 2024.

Timeline
11 July 2023
Primary endpoint
26 February 2024
26 February 2024

Quick facts

Lead sponsorWake Forest University Health Sciences
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date11 July 2023
Primary completion26 February 2024
Estimated completion26 February 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Wake Forest University Health Sciences

Who can join

18 and older, female only, with Voiding Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Urinary retention can lead to bladder over-distention, ischemia, and long-term voiding dysfunction, and early identification of urinary retention can help prevent these adverse events

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Control Group

Trials testing the same drug.

Other recruiting trials for Voiding Dysfunction

Currently open trials in the same condition.

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing